Bristol-Myers Squibb Co.BMY
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE · United States · bms.com
Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines in oncology, hematology, immunology, and cardiovascular disease. Key marketed products include Opdivo, Eliquis, Revlimid, and Yervoy, addressing serious diseases with significant unmet medical needs worldwide. The company is headquartered in Princeton, New Jersey.
Key ratios
Operating cash flow growth
-19.6%TTM
2025
-6.8%2024
9.6%2023
6.1%
EPS growth
82.7%TTM
2023
30.9%
FCF / Sales
23.3%TTM
2025
26.7%2024
28.9%2023
28.1%
Net margin
18.9%TTM
2025
14.6%2024
-18.5%2023
17.8%
ROA
10.7%TTM
2025
10.3%2024
6.6%2023
5.5%
ROE
46.6%TTM
2025
40.4%2024
-39.0%2023
26.5%
Revenue growth
3.1%TTM
2025
-0.2%2024
7.3%2023
-2.5%
Recent news
BioNTech und Bristol Myers Squibb präsentieren ermutigende Daten aus globaler Phase-2-Studie mit Pumitamig bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs nach Progression der Erkrankung unter einer Immuntherapie und Chemotherapie
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Track BMY in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer